Gender differences in the renal response to renin-angiotensin system blockade

Journal of the American Society of Nephrology

Volumn 17, Issue 9, 2006, Pages 2554-2560

  Miller, Judith A ^a,b   Cherney, David Z ^a   Duncan, John A ^a   Lai, Vesta ^a   Burns, Kevin D ^a   Kennedy, Christopher R J ^a   Zimpelmann, Joseph ^a   Gao, Wei ^a   Cattran, Daniel C ^a   Scholey, James W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; IRBESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; DISEASE MARKER; DRUG DOSE REGIMEN; FEMALE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; MALE; MICROVASCULATURE; NORMAL HUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SKIN BIOPSY;

EID: 33748050459     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005101095     Document Type: Article

References (30)

1. Silbiger SR, Neugarten J: The role of gender in the progression of renal disease. Adv Ren Replace Ther 10: 3-14, 2003
2. Fakhouri F, Placier S, Ardaillou R, Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C: Angiotensin activates collagen type 1 gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 12: 2701-2710, 2001
3. Hall JE, Brands MW, Henegar JR: Angiotensin II and long-term arterial pressure regulation: The overriding dominance of the kidney. J Am Soc Nephrol 10[Suppl 12]: S258-S265, 1999
4. Miller JA, Anacta L, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 55: 278-285, 1999
5. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW, Miller JA: Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol 280: R807-R813, 2001
6. Ahmed SB, Kang AK, Burns KD, Kennedy CRJ, Lai V, Cattran DC, Scholey JW, Miller JA: Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. J Am Soc Nephrol 15: 780-786, 2004
7. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, Miller JA: Variations in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 13: 446-452, 2002
8. Owonikoko TF, Fabucci ME, Brown PR, Nisar N, Hilton J, Mathews WB, Ravert HT, Rauseo P, Sandberg K, Dannals RF, Szabo Z: In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J Nucl Med 45: 94-100, 2004
9. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M: Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45: 545-551, 2005
10. Liu H-W, Iwai M, Takeda-Matsubara Y, Wu L, Li J-M, Okumura M, Cui T-X, Horiuchi M: Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 40: 450-457, 2002
11. Haddad G, Amiri F, Garcia R: Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism. Regul Pept 68: 111-117, 1997
12. Makino N, Sugano M, Otsuka S, Hata T: Molecular mechanism of angiotensin II type 1 and type 2 receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 30: 796-802, 1997
13. Nickenig G, Geisen G, Vetter H, Sachinidis A: Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 75: 217-222, 1997
14. Schnurr E, Lahme W, Kuppers H: Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 13: 26-29, 1980
15. Walser M, Davidson DG, Orloff J: The renal clearance of alkali-stable inulin. J Clin Invest 34: 1520-1523, 1955
16. Brun C: A rapid method for the determination of paraaminohippuric acid in kidney function tests. J Clin Lab Med 37: 955-958, 1951
17. Simon D, Hartmann DJ, Badouaille G, Caillot G, Guyenne TT, Corvol P, Pau B, Marchand J: Two-site direct immunoassay specific for active renin. Clin Chem 38: 1959-1962, 1992
18. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Bennini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 11: 88-96, 2000
19. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21, 1995
20. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR: Drug concentration response relationships in normal volunteers after oral administration of losartan, and angiotensin II receptor antagonist. Clin Pharmacol Ther 51: 513-521, 1992
21. Hagmann N, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR: SC-52458, an orally active angiotensin II-receptor antagonist: Inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol 29: 444-450, 1997
22. Püchler K, Nussberger J, Laeis P, Witte PU, Bruneer HR: Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 15: 1809-1812, 1997
23. Hubner R, Hogemann AM, Sunzel M, Riddell JG: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11: S19-25, 1997
24. Silbiger SR, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 4: 515-533, 1995
25. Clark MA, Tallant A, Bosch S, Diz D: Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J Cardiovasc Pharmacol 41: 276-283, 2003
26. Tanaka M, Tsuchida S, Imai T, Nobuharu F, Miyazaki H, Ichiki T, Naruse M, Inagami T: Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 receptor knockout mice. Biochem Biophys Res Commun 258: 194-199, 1999
27. Vachharajani NN, Shyu WC, Smith RA, Greene DS: The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46: 611-613, 1998
28. Marino MR, Vachharajani NN: Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 40: 112-122, 2002
29. Maillard MP, Würzner G, Nussberger J, Centeno C, Burnier M, Brunner HR: Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther 71: 68-76, 2002
30. Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A: Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. J Cardiovasc Pharmacol 37: 449-460, 2001